Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 22;9(4):e95776.
doi: 10.1371/journal.pone.0095776. eCollection 2014.

Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease

Affiliations

Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease

Jack X Q Pang et al. PLoS One. .

Abstract

Background: Liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) is a validated method for noninvasively staging liver fibrosis. Most hepatic complications occur in patients with advanced fibrosis. Our objective was to determine the ability of LSM by TE to predict hepatic complications and mortality in a large cohort of patients with chronic liver disease.

Methods: In consecutive adults who underwent LSM by TE between July 2008 and June 2011, we used Cox regression to determine the independent association between liver stiffness and death or hepatic complications (decompensation, hepatocellular carcinoma, and liver transplantation). The performance of LSM to predict complications was determined using the c-statistic.

Results: Among 2,052 patients (median age 51 years, 65% with hepatitis B or C), 87 patients (4.2%) died or developed a hepatic complication during a median follow-up period of 15.6 months (interquartile range, 11.0-23.5 months). Patients with complications had higher median liver stiffness than those without complications (13.5 vs. 6.0 kPa; P<0.00005). The 2-year incidence rates of death or hepatic complications were 2.6%, 9%, 19%, and 34% in patients with liver stiffness <10, 10-19.9, 20-39.9, and ≥40 kPa, respectively (P<0.00005). After adjustment for potential confounders, liver stiffness by TE was an independent predictor of complications (hazard ratio [HR] 1.05 per kPa; 95% confidence interval [CI] 1.03-1.06). The c-statistic of liver-stiffness for predicting complications was 0.80 (95% CI 0.75-0.85). A liver stiffness below 20 kPa effectively excluded complications (specificity 93%, negative predictive value 97%); however, the positive predictive value of higher results was sub-optimal (20%).

Conclusions: Liver stiffness by TE accurately predicts the risk of death or hepatic complications in patients with chronic liver disease. TE may facilitate the estimation of prognosis and guide management of these patients.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow diagram of study participants.
Figure 2
Figure 2. Unadjusted survival free of hepatic complications according to LSM by TE categorized as F0–1 (liver stiffness <7.1 kPa), F2 (7.1–9.4 kPa), F3 (9.5–12.4 kPa), and F4 (cirrhosis; ≥12.5 kPa).
Figure 3
Figure 3. Unadjusted survival free of hepatic complications according to LSM by TE categorized as <10 kPa, 10–19.9 kPa, 20–39.9 kPa, and ≥40 kPa.
Figure 4
Figure 4. Unadjusted survival free of hepatic complications according to the 20-threshold for liver stiffness.

References

    1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD (2009) Liver biopsy. Hepatology 49: 1017–1044. - PubMed
    1. Myers RP, Fong A, Shaheen AA (2008) Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 28: 705–712. - PubMed
    1. Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 38: 1449–1457. - PubMed
    1. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, et al. (2004) Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 3: 8. - PMC - PubMed
    1. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704–1713. - PubMed

Publication types

MeSH terms